ResearcherAin Shams UniversityNo recent work listed
Omar Mohammed Abdel-Rahman
Matched on ORCID iD 0000-0002-5117-2502; OpenAlex author ID A5108043749. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 2, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 2
- Collaborators
- 9
2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers
Papers 11
- Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. First author DOI 10.21037/tcr-23-720↗
- Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15041331↗
- Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management. First author DOI 10.2147/cmar.s340719↗
- Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1007/s12032-021-01469-y↗
- Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. Co-author DOI 10.2217/cer-2020-0079↗
- Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort. Last author DOI 10.1007/s12029-018-0158-4↗
- Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Co-author DOI 10.1007/s12094-018-1992-3↗
- A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1841↗
- Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma? Co-author DOI 10.1016/j.hbpd.2018.01.014↗
- Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. Last author DOI 10.1186/s12885-018-4610-4↗
- Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. Last author DOI 10.3748/wjg.v23.i10.1872↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaoyang Lan · 2 shared papers, 2023 · strength 0.63
- Paper Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal … DOI 10.21037/tcr-23-720↗
- Paper Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenoc… DOI 10.3390/cancers15041331↗
- Ali Fawaz · 1 shared paper, 2022 · strength 0.33
- Muneer J. Al‐Husseini · 2 shared papers, 2018–2019 · strength 0.24
- Paper Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort. DOI 10.1007/s12029-018-0158-4↗
- Paper Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based… DOI 10.1186/s12885-018-4610-4↗
- Anas M. Saad · 2 shared papers, 2018–2019 · strength 0.24
- Paper Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort. DOI 10.1007/s12029-018-0158-4↗
- Paper Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based… DOI 10.1186/s12885-018-4610-4↗
- Sheryl L. Koski · 1 shared paper, 2021 · strength 0.22
- Jennifer L. Spratlin · 1 shared paper, 2021 · strength 0.22
- Winson Y. Cheung · 1 shared paper, 2018 · strength 0.11
- Hani Oweira · 1 shared paper, 2017 · strength 0.07
- Jan Schmidt · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.